Development of FAPI PET as a Non-invasive Biomarker of Pulmonary Fibrogenesis
University of Wisconsin, Madison
Summary
The goal of this clinical trial is to gain more information about how fibroblast activation protein inhibitor (FAPI) binds to a certain type of cells in fibrotic lung tissue and how this information can be used to better diagnose and track fibrotic lung disease activity. Participants will undergo up to 4 PET/MRI scans using the FAPI radiotracer.
Description
Researchers aim to develop a non-invasive PET/MRI imaging tool using FAPI as a PET radiotracer and MRI to assess the presence and extent of fibrogenesis (the process that leads to fibrosis and scarring) in the lungs.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Age 18 years or older * Able and willing to provide informed consent * Group A: Clinically evaluated for need for initiation of new treatment (in patients not on current treatment), initiation of change in current treatment, or addition of new treatment (to any current treatment) in the setting of fibrotic hypersensitivity pneumonitis (HSP) or idiopathic pulmonary fibrosis (IPF), per standard of clinical care at UW Health. * Group B: Clinically evaluated and stable without need for initiation of new treatment (in patients not on current treatment), initiation of change i…
Interventions
- DrugFAPI tracer
radioactive substance called a "tracer" injected into the arm
- DevicePET/MRI
positron emission tomography (PET) takes pictures of inside of the body
Location
- University of Wisconsin - MadisonMadison, Wisconsin